Journal Guide

Clinical Neuropharmacology is the leading journal of reviews and original investigations in this field. The journal is devoted to the pharmacology of the nervous system in the broadest sense, with topics ranging from basic mechanisms of action, structure-activity relationships, drug metabolism, and pharmacokinetics, to such practical clinical problems as drug interactions, drug toxicity, and the therapeutics of specific syndromes or symptoms. Disorders often classified as psychiatric, as well as classical neurological disorders, are included. Website: www.clinicalneuropharm.com.

Clinical Pharmacokinetics is the major review journal in the area of clinical pharmacokinetics, the study of drug disposition in the human body, which is an integral part of drug development and rational use.

Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles and Reports in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.Commentaries and Point-Counterpoint provide a forum for perspectives in clinical pharmacology and therapeutics in the context of contemporary scientific, political, economic and social issues. State of the Art contributions summarize the latest advances in the science underpinning drug discovery, development, regulation and utilization. CPT highlights issues transforming the practice of clinical pharmacology, including ethics, education and public policy. Bench-to-bedside translation in therapeutics is presented in the context of clinical applications of basic pharmacology, discovery and translational medicine, and drug development.

Medicine/Public Health general, Gynecology, Pneumology/Respiratory system, Gastroenterology, Pediatrics

Every paper has its own priorities. Be it rapid publication, strong circulation, society affiliation or the prestige of a high Impact Factor, we help pharmaceutical companies, medcomms agencies and medical writers identify the Informa Healthcare journal that will help them achieve their publication objectives.We actively encourage pre-submission discussions with our team and Informa Healthcare editors to ensure your submission process is as efficient and effective as possible. You are welcome to contact us directly to discuss your upcoming manuscripts. Alternately, if you would like to browse our portfolio of 168 journals, you can do so using the tool below.

Clinical Therapeutics is dedicated to the dissemination of reliable and evolving evidence derived from clinical pharmacology and other therapeutic approaches to an international audience of scientists and clinicians working in a variety of research, academic, and clinical practice settings. Providing such information is especially important in this era of harmonization and globalization of drug development. Clinical Therapeutics strives to achieve its mission by providing peer-reviewed, rapid publication of recent developments in drug therapies, as well as in-depth review articles on specific agents, treatment strategies, and disease states. Most articles are available online within 20 business days after acceptance. Articles appearing in Clinical Therapeutics are indexed by all major biomedical abstracting databases.Published articles range from pivotal studies exploring new chemical entities in large, multicenter trials to those exploring repurposing of marketed agents. Additionally, pilot studies; reports that assess drug safety and tolerability in all phases of development; new routes of administration and new formulations; pharmacokinetic, bioavailability, bioequivalence and biosimilarity; and changes in practice guidelines and standards, are all of interest for publication. Clinical Therapeutics also understands the importance of strengthening the body of evidence surrounding particular agents through the publication of replication studies, negative trials, and failed trials. Beyond the clinic, we seek reports that examine the real-world implications of therapeutics such as comparative effectiveness and pharmacoeconomics studies as well as work that has implications for health policy. Commentaries, which include perspectives and contemporary issues, are sought to offer a balance of viewpoints and scholarly opinion on a broad array of drug-related topics. Case reports, which remain a vital part of our mission, offer clinically valuable lessons. All manuscripts are peer reviewed by independent clinicians or scientists for clinical relevance, technical accuracy, methodological rigor, clarity, and objectivity using a blind review process.

Clinical Trials: Journal of the Society for Clinical Trials is an international peer reviewed scholarly journal whose primary aim is the dissemination and development of knowledge about the design, conduct, analysis, synthesis, history, ethics, regulation and clinical or policy impact of all types of clinical trials and related medical research methodologies.

Clinical and Experimental Pharmacology and Physiology provides a medium for the rapid publication of original research papers, short communications, rapid communications and theoretical articles (hypotheses) on the results of clinical and experimental work in pharmacology and physiology. Invited review articles are published occasionally. The Journal aims to make a substantial contribution to effective and productive communication between scientists throughout the world who are working in these interrelated disciplines. Clinical and Experimental Pharmacology and Physiology has been adopted by the High Blood Pressure Research Council of Australia (HBPRCA) and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT).

Computers & Geosciences publishes high impact, original research at the interface between Computer Sciences and Geosciences. Publications should apply modern computer science paradigms, whether computational or informatics-based, to address problems in the geosciences.Computational/informatics elements may include: computational methods; algorithms; data structure; database retrieval; information retrieval; data processing; artificial intelligence; computer graphics; computer visualization; programming languages; parallel systems; distributed systems; the World-Wide Web; social media; and software engineering.Geoscientific topics of interest include: mineralogy; petrology; geochemistry; geomorphology; paleontology; stratigraphy; structural geology; sedimentology; hydrogeology; oceanography; atmospheric sciences; climatology; meteorology; geophysics; geomatics; remote sensing; geodesy; hydrology; and glaciology.Other fields may be considered but are not regarded as a priority.Computers & Geosciences does not consider:Pure methodology papers (without computer science)Standard code of already well-established, or previously published methodsGraphical User Interfaces (GUIs), unless they provide an original solution to a non-trivial input-handling problemPapers which use GIS tools in only standard ways, but are otherwise largely focused on the geoscience disciplineSubmissions from fields such as mining engineering, petroleum engineering, geotechnical engineering, rock-mechanics and others, unless such submissions contain a significant geosciences component. For instance, a mining paper only dealing with transport problems, a geotechnical paper on lab experiments, or a paper on rockbolting, would be considered unsuitable.Code and Data:Computers & Geosciences aims to publish code and supporting data from accepted manuscripts using state-of-the-art technologies. Code should be original and demonstrate a development in research. It should also have clear design and be reproducible, reusable, extensible and maintainable. The journal uses the github.com platform (search for: CAGEO) which allows the community to publish, maintain, update and comment on published code and data.Paper Types:Original research article (5,000 words): Providing a novel and original contribution to the scientific fields of study outlined above.Application article (5,000 words): Describing a real-world case study on the scientific fields of study outlined above.Scientific review article (10,000 words): Critically describing the state-of-the art of applications of computer science in the geosciences, as a stand-alone contribution or to frame a special issue. Criteria for assessment shall be: completeness, depth, novelty, timeliness, quality, and interest to the Journal's readership. Review outlines should be pre-approved by an Associate Editor, or Editorial Board Member of the Journal.Book and software reviews (1500 words): Describing and evaluating a new or significant publication or piece of software relevant to aspects of computation or informatics in the geosciences.Letter to the Editor: Commenting on published articles. Criteria for assessment shall be the merit of the question or comment raised. The author(s) of the commented-on article shall be offered the opportunity to prepare a reply, to be published alongside the comment.

Contemporary Clinical Trials Communications is unique in that it is outside the confines of disease specifications, and it strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings irrespective of their perceived importance, significance or impact. Both randomized and non-randomized trials are within the scope of the Journal. Some common topics include trial design rationale and methods, operational methodologies and challenges, and positive and negative trial results. In addition to original research, the Journal also welcomes other types of communications including, but are not limited to, methodology reviews, perspectives and discussions.

Through timely dissemination of advances in clinical trials, the goal of Contemporary Clinical Trials Communications is to serve as a platform to enhance the communication and collaboration within the global clinical trials community that ultimately advances this field of research for the benefit of patients.

Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields.Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly diffcult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.

The aim of this journal is to keep readers informed by providing cutting-edge reviews on key topics pertaining to cardiovascular risk. We use a systematic approach: international experts prepare timely articles on relevant topics that highlight the most important recent original publications.

We accomplish this aim by appointing Section Editors in major subject areas across the discipline of cardiovascular medicine to select topics for review articles by leading experts who emphasize recent developments and highlight important papers published in the past year. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.

Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism, pharmacokinetics, and drug disposition. The journal serves as an international forum for the publication of full-length/mini review, research articles and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the most important developments. The journal covers the following general topic areas: pharmaceutics, pharmacokinetics, toxicology, and most importantly drug metabolism.
More specifically, in vitro and in vivo drug metabolism of phase I and phase II enzymes or metabolic pathways; drug-drug interactions and enzyme kinetics; pharmacokinetics, pharmacokinetic-pharmacodynamic modeling, and toxicokinetics; interspecies differences in metabolism or pharmacokinetics, species scaling and extrapolations; drug transporters; target organ toxicity and interindividual variability in drug exposure-response; extrahepatic metabolism; bioactivation, reactive metabolites, and developments for the identification of drug metabolites. Preclinical and clinical reviews describing the drug metabolism and pharmacokinetics of marketed drugs or drug classes.

Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.

Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes.

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.